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Abstract
Objective The objective of this study was to evaluate the
cost effectiveness of lubiprostone, prucalopride, placebo
and immediate referral to secondary care in chronic idio-
pathic constipation (CIC) in an economic model that was
used by the UK National Institute for Health and Care
Excellence (NICE) in developing guidance.
Methods We developed a cohort state-transition model to
reflect the treatment pathway in CIC from the UK NHS and
personal social services perspective. Time on treatment
was determined by a treatment continuation rule using data
from an indirect comparison and survival curves fitted to
long-term data. Quality of life was defined by whether CIC
was resolved or unresolved, using published values. Costs
were determined by drug acquisition costs, invasive pro-
cedures and healthcare resource use (associated with
resolved or unresolved CIC), using published UK sources.
Deterministic and probabilistic sensitivity analyses were
conducted.
Results Over a 10-year time horizon, lubiprostone was
more costly and more effective than placebo and
immediate referral to secondary care, with incremental
cost-effectiveness ratios (ICERs) of £58,979 and £21,152.
Lubiprostone dominated prucalopride in the base case and
with a time horizon of 1 year. The main sensitivity for the
comparison against placebo was the assumptions around
placebo cost and efficacy. The main sensitivity for the
comparison against prucalopride was the endpoint used in
the indirect comparison.
Conclusion Lubiprostone may be cost effective compared
with prucalopride or immediate referral but not compared
with placebo in the base case. The implementation of the
guidance issued by NICE should increase quality of life for
patients with CIC and provide a further treatment option.
Key Points for Decision Makers
There is large uncertainty in the clinical pathway for
chronic idiopathic constipation.
Multiple indirect comparisons are possible between
treatments using different endpoints.
Lubiprostone appears to be a cost-effective option at
UK list price compared with prucalopride and
immediate referral.
1 Introduction
Chronic idiopathic constipation (CIC) is a common disor-
der characterized as constipation over an extended time
period with no known cause. The most widely accepted
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definition of CIC uses the Rome IV diagnostic criteria [1],
which requires that patients fulfil certain symptom criteria
relating to their bowel habit, including the relative fre-
quency of defecations [2]. It is distinct from irritable bowel
syndrome in that abdominal pain is not the key feature.
CIC has a severe impact on the health and wellbeing of
patients, with the size of the effect comparable to that of
musculoskeletal diseases, diabetes, heart disease and
depression [3, 4].
As disease onset is slow [5] and diagnosis is often
delayed because patients self-medicate, the exact preva-
lence of CIC is unknown [6]. One estimate suggests that
approximately 570,000 adult patients in England and
Wales have general practitioner (GP)-diagnosed constipa-
tion [6]. The diagnosis involves taking a detailed history,
excluding secondary causes, and investigations as appro-
priate. Depending on the patient’s symptoms and the
physician, investigation may include blood tests, colono-
scopy, transit studies and anorectal physiology.
Lubiprostone (Amitiza, Takeda UK Ltd) is a locally
acting chloride channel-2 activator. The safety and efficacy
of lubiprostone in CIC was studied in three phase III ran-
domized controlled trials (RCTs) (n = 603) [7–9]. These
studies demonstrated that lubiprostone significantly
increased spontaneous bowel movements (SBMs) and
other clinically relevant endpoints compared with placebo.
Evidence of sustained efficacy is also available from four
long-term open-label studies [9–12].
In the UK, the National Institute for Health and Care
Excellence (NICE) seeks to review the clinical and cost-
effectiveness evidence of new medicines, aiming to max-
imize the health (defined in terms of quality-adjusted life-
years [QALYs]) of the population within a fixed healthcare
budget. In August 2013, NICE elected to assess lubipros-
tone as a treatment for CIC in a single technology
appraisal. The scope of the appraisal was to compare
lubiprostone with bulk-forming, osmotic and stimulant
laxatives and prucalopride in a population of adults with
CIC, when response to diet and other non-pharmacological
measures are inappropriate [13]. The cost-effectiveness
results considered in developing the final appraisal deter-
mination are reported elsewhere [14]. In this study, we
describe the economic model and inputs, update the costs
to year 2016 values and report results of a less conservative
analysis (using most likely estimates for parameters
according to expert validation) in which we considered a
longer time horizon, such that patients were in comparable
states at the end of the model, and an additional comparator
to reflect the clinical pathway in the UK.
2 Methods
2.1 Model Structure
There is no consensus pathway for the management of CIC,
so we conducted advisory boards with clinical experts. The
five experts involved in the process were clinicians cur-
rently working in the UK NHS in a variety of settings,
including one GP, three secondary care consultant gas-
troenterologists and one gastrointestinal medicine expert.
Their views were collected in a questionnaire prior to
meeting and then through discussion to reach unanimous
agreement. Their unanimous view was that lubiprostone
would be used when at least two laxatives had failed,
because many inexpensive laxatives would have been used
before this. The objective of treatment at this stage is to
treat patient’s symptoms and avoid unnecessary referrals to
investigations and invasive procedures.
We constructed a cohort state-transition model in
Microsoft Excel. State-transition models are appropriate
where a disease can be categorized into mutually exclusive
and collectively exhaustive states and where any individ-
uals in the same health state have the same quality of life
and the same healthcare resource use. The health states
were chosen to reflect the treatment pathway and whether a
person had resolved or unresolved CIC. The health states in
the model were as follows:
• ‘treatment’, during which patients receive lubiprostone,
placebo or prucalopride,
• ‘investigations/invasive procedures’, in which all
patients visit a gastroenterologist, 95% have a colono-
scopy, and 61% undergo invasive procedures (of which
98.9% are biofeedback, 1.0% are sacral neuromodula-
tion, 0.1% are stoma surgery) [15],
• ‘resolved’, which patients enter if the invasive proce-
dures are curative (95% probability for sacral neuro-
modulation and stoma surgery, 62% for biofeedback)
[16], and
• ‘unresolved’, which patients enter if they have been
treated with lubiprostone or prucalopride and invasive
procedures are either not received or not curative.
Figure 1 shows the structure of the economic model. We
used a cycle length of 2 weeks—the duration of the initial
trial period of lubiprostone.
The perspective of the model was NHS and personal
social services. Costs and QALYs were discounted annu-
ally at 3.5% [17]. The NICE reference case for economic
evaluation stipulates that the time horizon for estimating
clinical and cost effectiveness should be sufficiently long to
reflect any differences in costs or outcomes between the
technologies being compared. For a comparison against
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another active drug (prucalopride), a short time horizon is
sufficient. However, for comparison with immediate
referral, a longer time horizon is required to capture all
relevant differences and ensure patients are in comparable
health states at the end of the model period. We therefore
present results for a 1-year time horizon (as considered by
NICE) and for a 10-year time horizon.
2.2 Comparators
We considered prucalopride, placebo and immediate
referral to secondary care as comparators. Prucalopride is
arguably the most relevant comparator, as it is licensed and
recommended in the same indication [18]. However,
questions remain over what the most appropriate com-
parator is where prucalopride is not used. In the NICE
appraisal, placebo was considered as a comparator and was
assumed to be representative of standard laxative treatment
(which patients received alongside placebo in the trial).
Since referrals to investigations and invasive procedures
are being considered in this indication, we included
immediate referral to secondary care as an additional
comparator.
2.3 Clinical Inputs
On the advice of clinicians, the economic model incorpo-
rated a treatment continuation rule that determined whether
or not a patient had adequately responded and should
continue treatment beyond the initial period.
The initial period for lubiprostone and placebo is
2 weeks, based on the UK summary of product character-
istics for lubiprostone [19]. In order to continue treatment
after the initial trial period, patients must have had three or
more SBMs with no use of rescue medication during week
2; for placebo, this was 53.5% of patients based on a meta-
analysis of the RCTs. The relative risk of response at week
2 for lubiprostone compared with placebo was 1.30 [20].
The initial trial period for prucalopride is 4 weeks
before response is assessed [21, 22]. When response at
week 4 is defined as having three or more SBMs with no
use of rescue medication during week 4, a total of 50.0% of
patients receiving placebo responded and the relative risk
of response at week 4 for lubiprostone compared with
placebo was 1.38. The probability of response at week 4 for
prucalopride was calculated by multiplying the placebo
response by the relative risk for lubiprostone versus pla-
cebo and dividing by the relative risk for lubiprostone
versus prucalopride.
The relative risk for lubiprostone versus prucalopride
was calculated from indirect comparisons. The RCTs for
lubiprostone and prucalopride had different primary end-
points, and the prucalopride trial did not include the defi-
nition of response used in the lubiprostone analysis.
Therefore, the relative effectiveness of lubiprostone versus
prucalopride was estimated from other outcomes. Several
outcomes were common to both lubiprostone and
prucalopride trials, which permitted indirect comparisons
to be performed for seven different measures (Table 1).
The indirect comparisons used the Bucher approach [23],
and methods are described elsewhere [20, 23]. The base
case used the ‘change in SBM from baseline’ (the primary
endpoint of the lubiprostone studies), which showed
numerical superiority for lubiprostone over prucalopride
without reaching statistical significance. The relative
effectiveness of prucalopride compared with lubiprostone
was applied in the model to the definition of response.
To incorporate treatment discontinuation beyond the
stopping rule at week 2 or 4, parametric curves were fitted
to discontinuation data beyond week 2 from the long-term
open-label lubiprostone studies combined with long-term
US prescription data [12]. The rate of discontinuation after
implementation of the treatment continuation rule was
assumed to be the same for prucalopride as for lubiprostone
because the reasons for discontinuation would be similar.
The best-fitting curve, according to visual inspection,
Akaike information criterion and Bayesian inference cri-
terion, was the log-logistic, with scale parameter 4.26 and
shape parameter 0.24. For placebo, the base-case scenario
considered that patients discontinued treatment using the
same data, and a scenario analysis considered that placebo
had no lasting effect after the initial 2-week period, with all
patients then discontinuing to be moved to investigative
treatment.
Patients who responded to treatment remained on
treatment until they discontinued. After non-response (at
week 2 for lubiprostone or week 4 for prucalopride) or
discontinuation, patients moved immediately into the ‘in-
vestigations/invasive procedures’ health state, where they
Fig. 1 Economic model structure. The dashed line indicates transi-
tion is considered in the scenario analysis only and not in the base
case
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remained for one cycle. A proportion of patients moved
from ‘investigations/invasive procedures’ into ‘resolved’
and the remainder into ‘unresolved’, where they remained
until the end of the model time horizon.
All-cause mortality was included in the model, using
age- and sex-specific mortality data from life tables for
England and Wales [24]. In the base case, it was assumed
that CIC affected only quality of life and not survival.
There is some evidence that constipation may be linked to
increased mortality [25–28], so a scenario was considered
using a hazard ratio for mortality of 1.19 for unresolved
versus resolved CIC [29].
2.4 Health-Related Quality of Life
A large (n = 1200) study in CIC enrolling patients in the
USA and Canada reported EuroQol Five-Dimension (EQ-
5D) utility scores at baseline (0.83) and for responders
(0.90) and non-responders (0.86) [30]. The model assumed
that the utility in the initial trial period for placebo,
lubiprostone and prucalopride was an average of responder
and non-responder utilities, weighted for the proportion of
responders for each treatment. Beyond the initial period,
the utility value for patients who continued on treatment
was that of a responder, since they had, by definition,
responded to treatment. Patients undergoing invasive pro-
cedures were non-responders to treatment and so had the
utility value for a non-responder. Following invasive pro-
cedures, patients who were cured had the utility value for a
responder. Those whose condition remained unresolved
were assumed to have a poorer quality of life than those at
an earlier stage in the pathway and were not assumed to
receive active treatment, so had the utility value from
baseline (Table 2).
2.5 Costs
All patients in the economic model receiving lubiprostone,
placebo or prucalopride incurred the cost of the initial
treatment period before response was assessed. Lubipros-
tone (dosed 24 lg twice daily) was available in a 2-week
starter pack (28 tablets), costing £29.68 [31]. Beyond this
initial period, patients who met the treatment continuation
rule continued to receive lubiprostone in a larger pack of 56
tablets (4 weeks), costing £53.48 [31]. Prucalopride (dosed
2 mg once daily in adults and 1 mg once daily in the
elderly), is available only in 4-week (28 tablets) packs
costing £59.52 (2 mg) and £38.69 (1 mg) [31]. In the
pivotal lubiprostone trials, 11.3% of patients were
aged[65 years [7–9]. To create an unbiased comparison,
this percentage of patients aged[65 years from the
lubiprostone trials was used, which led to a weighted cost
of £57.17 for prucalopride. All patients receiving
prucalopride incurred this cost before response was asses-
sed (at 4 weeks).
In the NICE submission, placebo was assumed to have
no cost. However, since placebo is assumed to be repre-
sentative of further laxative treatment, placebo was costed
in our revised analysis as the simple average of all standard
laxative treatments (including bulk-forming laxatives,
stimulant laxatives and osmotic laxatives), as per Table 72
of the evidence review group (ERG) report, with drug costs
taken from the British National Formulary (BNF) [31, 32].
In the clinical trials for lubiprostone, patients could be
given rescue medication if they had no SBM for 3 con-
secutive days. The proportions of patients receiving
lubiprostone or placebo who required a bisacodyl (Dulco-
lax) suppository as rescue medication were 30 and 39% in
weeks 1–2 and 15 and 20% in weeks 3–4, respectively (see
Table 1 in the Electronic Supplementary Material [ESM]).
The proportion of prucalopride-treated patients requiring
Table 1 Relative risks derived from indirect comparisons of lubiprostone versus prucalopride
Outcome Lubiprostone vs. prucalopride Favours
RR (95% CI)
Change in SBM from baseline 1.12 (0.77–1.64) Lubiprostone
Percentage of patients achieving an average increase in SBM ofC 1 over weeks 1–4 1.04 (0.84–1.28) Prucalopride
SBMs rated as ‘normal’ 0.73 (0.63–0.85) Prucalopride*
SBMs rated as ‘hard’ or ‘very hard’ 0.78 (0.60–1.01) Lubiprostone
SBMs with no straining 1.27 (0.79–2.03) Lubiprostone
SBMs with severe/very severe straining 0.67 (0.48–0.92) Lubiprostone*
Mean change in SCBM from baseline over weeks 1–4 2.60 (0.59–4.61) Lubiprostone
Assume same efficacy 1.00 Neither
CI confidence interval, RR relative risk, SBM spontaneous bowel movement, SCBM spontaneous complete bowel movement
*p\0.05
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rescue medication was assumed to be the same as that for
those receiving lubiprostone. A 12-pack of 10-mg Dulco-
lax suppositories costs £3.53 according to the BNF [31].
The mean ingestion rate of lubiprostone for patients on
treatment in the clinical trials was 83% (standard error
1.5%) [33], so reduced dosing was considered for
lubiprostone in the base case. For the scenarios focusing on
comparison with prucalopride, full dosing of both
lubiprostone and prucalopride was assumed as data on
reduced dosing for prucalopride were not available. All
treatments may be prescribed either in primary care by a
GP or in secondary care during an outpatient appointment
with a gastroenterologist [32]. The base case in the eco-
nomic model assumed it was equally likely (50:50 split)
that these were initiated by a GP or a gastroenterologist.
Assessment of the treatment continuation rule was assumed
in the base case to be performed through a telephone
consultation, 80% of which were assumed to be with a
nurse and the remainder with a GP.
Medical resource use was defined by whether a patient
was receiving active treatment and whether their consti-
pation was resolved or unresolved. Another study in con-
stipation reported the frequency of accident and emergency
visits, hospital outpatient visits, laboratory tests and GP
contact for patients receiving Macrogol 4000 and lactulose
over 3 months [34]. Resource use was reported separately
for monotherapy and combination therapy, for patients who
remained on initial therapy, switched therapy or discon-
tinued therapy. It was assumed that patients on initial
therapy represented those on initial therapy in our model,
those who switched therapy represented those whose CIC
was unresolved, and those who discontinued therapy were
resolved, averaging Macrogol 4000 and lactulose. The
costs of resources were taken from NHS Reference Costs
2015–16 [35] and Personal Social Services Research Unit
(PSSRU) Unit Costs of Health and Social Care 2016 [36].
Costs for referral to investigations and invasive procedures
were taken from the NICE assessment of prucalopride,
Table 2 Health state costs and utilities
Costs Number of units per 2-week cycle Investigations/
invasive
procedures
Sources
Item Unit
cost
(£)
Source On treatment Resolved Unresolved
GP home visit 100a PSSRU 2016 [36] 0.0161 0.0092 0.0345 0.0345 Guest et al.
[34] 2008GP telephone
consultations
14 0.0387 0.0176 0.0552 0.0552
GP clinic visit 31 0.4734 0.1549 0.5044 0.5044
Laboratory test 3 NHS reference costs
2015–16 [35]
0.0448 0.0222 0.0606 0.0606
Accident and
emergency visit
115 0.0015 0.0008 0.0023 0.0023
Hospital outpatient
appointment
(follow-up)
132 0.0134 0.0092 0.0123 0.0123
Hospital outpatient
appointment (first
attendance)
165 1 Expert
opinion
Colonoscopy 371 0.95
Stoma surgery 1310 PRU NICE costing
template, inflated to
2015–16 [43]
0.001 PRU NICE
costing
template
[43]
Sacral
neuromodulation
9660 0.01
Biofeedback 792b 0.989
Total cost £18.97 £7.39 £22.00 £1056.74
Utility value Huang et al. [30] 2012 Before stopping rule: PL 0.88;
LUB 0.89; PRU 0.88. After
stopping rule: 0.90
0.90 0.83 0.86 Huang et al.
[30] 2012
GP general practitioner, LUB lubiprostone, NICE UK National Institute for Health and Care Excellence, PL placebo, PRU prucalopride, PSSRU
Personal Social Services Research Unit
aAssumed half hour GP time
bSix outpatient follow-up appointments
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updated to year 2016 values [15]. Table 2 shows the costs
and utilities.
2.6 Model Validation
Before the model was submitted to NICE, a senior health
economist with no involvement in the project verified and
critiqued the model according to a checklist to determine
whether the calculations were appropriate and correct.
Subsequently, as part of the NICE process, the model was
verified and critiqued by an independent academic centre
and discussed by an expert committee to validate the
structure, assumptions and inputs [37].
2.7 Analysis
The base-case analysis presented here makes three changes
to the scenario considered by NICE. First, the cost of
placebo treatment was included to reflect the costs of lax-
ative treatment, and immediate referral was added as a
comparator. Second, the costs were updated by using 2016
sources. Third, the time horizon was extended to 10 years
to ensure patients receiving immediate referral were in
health states comparable to those receiving lubiprostone,
prucalopride or placebo at the end of the model.
Deterministic and probabilistic analyses were performed
for the base-case analysis. Probabilistic sensitivity analysis
was conducted by simultaneously sampling each parameter
from its probability distribution and calculating the total
costs and QALYs for each arm. This was done 1000 times
(as the result stabilised by this point), and the mean total
costs and QALYs for each arm from the 1000 simulations
were used to calculate incremental results. Distributions for
cost, resource use and utilities are shown in Table 1 in the
ESM. Response to placebo was sampled from a beta dis-
tribution with alpha equal to the number of responders and
beta the number of non-responders. Relative risks for
lubiprostone versus placebo and for prucalopride versus
lubiprostone were sampled from log-Normal distributions.
Discontinuation parameters were sampled from a multi-
variate Normal distribution. For the base case, the proba-
bility that each treatment is the most cost effective at a
threshold of £20,000 per QALY was calculated (the lower
end of the suggested NICE ‘threshold’ for determining a
cost-effective medicine) [17]. This analysis was performed
to capture parameter uncertainty.
One-way deterministic sensitivity analysis was con-
ducted by setting each parameter in turn to the lower and
then upper bound of its 95% confidence interval. This
analysis was performed to explore the key drivers of the
cost-effectiveness results.
Scenario analyses were performed for the six other
indirect comparisons possible between lubiprostone and
prucalopride (in addition to testing the assumption of equal
efficacy). A scenario where CIC influenced mortality was
considered, as was a scenario where placebo had no lasting
effect beyond 2 weeks. These scenarios explored the
structural uncertainty associated with model assumptions.
3 Results
3.1 Patient Flow
After the initial treatment period, 69.3 and 61.5% of
patients were eligible to continue treatment with lubipro-
stone or prucalopride, respectively. After 1 year, 8.1% of
patients remained on lubiprostone, 8.1% on prucalopride,
and 6.0% on placebo. After 10 years, all patients had dis-
continued lubiprostone, prucalopride or placebo. Figure 2
shows the proportion of patients in each health state over
the time horizon for each treatment.
3.2 Base-Case Results
Table 3 presents the results of the deterministic analysis
considered by NICE and the stepwise changes to meet the
(deterministic and probabilistic) base case for this analysis.
The base-case deterministic results show that immediate
referral is both the least costly and the least effective
option. Placebo (representing standard care) is more
expensive and generates more QALYs, with a resulting
incremental cost-effectiveness ratio (ICER) of £9909/
QALY. Lubiprostone is more expensive and more effective
than placebo and immediate referral as patients spend
longer on treatment, generating both costs and QALYs.
Lubiprostone has an ICER of £58,979 compared with
placebo or £21,152 compared with immediate referral. This
means that lubiprostone is not cost effective compared with
placebo but is cost effective compared with immediate
referral at a threshold of £30,000/QALY. Prucalopride is
more costly than lubiprostone, primarily because the drug
costs are higher, but less effective than lubiprostone based
on the results of the indirect comparison and patients
spending less time on treatment due to this lower efficacy.
Prucalopride is therefore dominated by lubiprostone.
3.3 Sensitivity Analyses
3.3.1 Probabilistic Sensitivity Analyses
Table 3 contains probabilistic base-case results, and Fig. 3
shows a cost-effectiveness acceptability curve for the four
options. At a willingness to pay below approximately
£10,000 per QALY, the most cost-effective option is
immediate referral. As willingness to pay increases,
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Fig. 2 Patient flow
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lubiprostone and prucalopride become more attractive
options. At around £40,000–50,000/QALY, prucalopride
has a higher probability of being cost effective than
lubiprostone as, in some simulations, prucalopride is more
effective than lubiprostone and has a lower ICER com-
pared with placebo than does lubiprostone. Conversely, in
the scenarios where lubiprostone is more effective than
prucalopride, the ICERs for both prucalopride and
lubiprostone versus placebo are above £50,000, so placebo
is the most cost-effective treatment. At around £60,000/
QALY, lubiprostone has a higher probability of being cost
effective than placebo. As the willingness to pay increases,
both lubiprostone and prucalopride increase in probability
of being the optimum treatment; however, both rise in
tandem because of the uncertainty in the relative efficacy.
3.3.2 Deterministic Sensitivity Analyses
Figure 4 shows the tornado diagrams for the comparison
between lubiprostone and placebo and between lubipros-
tone and prucalopride. These two comparisons are pre-
sented as they represent the decision problem considered
by NICE. The comparison between lubiprostone and pla-
cebo used base-case settings. The net benefit of lubipros-
tone compared with placebo using a threshold of £20,000
(incremental QALYs 9 £20,000 threshold- incremental
costs) was always negative, showing that, even at the upper
and lower bounds of each parameter, lubiprostone was not
cost effective compared with placebo.
The biggest drivers were the response rate for placebo,
proportion of patients cured by biofeedback and the utility
value for responders. When more placebo-treated patients
responded, the response rate for lubiprostone also increased
and the costs and QALYs for both arms increased—but the
Table 3 Base-case economic model results
Variables Total Incremental ICER (£) ICER vs. baseline (£)
Costs (£) LYs QALYs Costs (£) LYs QALYs
NICE analysis
Placebo 1506 0.9958 0.8619
Lubiprostone 1672 0.9958 0.8645 165 0.0000 0.0026 64,464 64,464
Prucalopride 1713 0.9958 0.8643 41 0.0000 - 0.0002 Dominated 87,085
NICE analysis, with placebo cost, and immediate referral added
Immediate referral 1455 0.9958 0.8532
Placebo 1522 0.9958 0.8619 67 0.0000 0.009 7756 7756
Lubiprostone 1672 0.9958 0.8645 149 0.0000 0.003 58,256 19,279
Prucalopride 1713 0.9958 0.8643 41 0.0000 0.000 Dominated 23,358
NICE analysis, with placebo cost, and immediate referral added, year 2016 values
Immediate referral 1527 0.9958 0.8532
Placebo 1573 0.9958 0.8619 46 0.00 0.009 5287 5287
Lubiprostone 1717 0.9958 0.8645 145 0.00 0.003 56,549 16,984
Prucalopride 1759 0.9958 0.8643 42 0.00 0.000 Dominated 21,084
Base-case: deterministic analysis
NICE analysis, with placebo cost, immediate referral added, and 10-year time horizon
Immediate referral 4755 8.5324 8.4812
Placebo 4889 8.5324 8.4947 134 0.00 0.014 9909 9909
Lubiprostone 5126 8.5324 8.4987 237 0.00 0.004 58,979 21,152
Prucalopride 5195 8.5324 8.4985 69 0.00 0.000 Dominated 25,324
Base case: probabilistic analysis
Immediate referral 4744 8.5308 8.4808
Placebo 4879 8.5308 8.4945 135 0.0000 0.0136 9869 21,129
Lubiprostone 5118 8.5308 8.4986 240 0.0000 0.0041 58,795 58,795
Prucalopride 5192 8.5308 8.4986 74 0.0000 0.0001 777,053 75,178
ICER incremental cost-effectiveness ratio, LYs life-years, NICE UK National Institute for Health and Care Excellence, QALYs quality-adjusted
life-years
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relative increase in costs was greater for lubiprostone, so
the ICER increased. When the effectiveness of biofeedback
increased, biofeedback became more cost effective—since
more placebo-treated patients underwent biofeedback, the
cost effectiveness of placebo increased. When the utility
value for responders increased, the quality-of-life benefit of
lubiprostone increased, leading to an increase in the net
benefit of lubiprostone.
The comparison between lubiprostone and prucalopride
used base-case settings but an ingestion rate of 100% for
lubiprostone. The net benefit of lubiprostone using a
threshold of £20,000 was always positive—showing that,
even at the upper and lower bounds of each parameter,
lubiprostone was cost effective compared with prucalo-
pride. The biggest drivers were the proportion having a GP
visit (rather than a consultation with a gastroenterologist)
to prescribe each drug, and the relative efficacy of
lubiprostone and prucalopride. It is unsurprising that one
drug would become more cost effective than the other if it
could be prescribed in primary rather than secondary care
whereas the other could not. The impact of relative efficacy
was explored in scenario analyses.
3.3.3 Scenario Analyses
We conducted deterministic and probabilistic scenario
analyses varying the relative effectiveness of lubiprostone
and prucalopride using different outcomes from the indi-
rect comparison. In all cases, the incremental net benefit at
£20,000/QALY was positive for lubiprostone. Even where
prucalopride was more effective than lubiprostone, it was
not cost effective compared with lubiprostone as the
additional cost resulting from the higher treatment cost and
longer duration was not sufficiently outweighed by the
QALYs gained at standard willingness-to-pay thresholds.
In an analysis using a different source of utilities [34],
the difference between responder and non-responder was
greater, so the ICER for lubiprostone versus placebo
decreased to £49,802/QALY (as lubiprostone provided
more time in a responder health state).
In a scenario including increased mortality for unre-
solved CIC, the absolute life-years and QALYs for each
treatment decreased. However, since there was a mortality
benefit to remaining on treatment, the incremental QALYs
for placebo versus immediate referral and lubiprostone
versus placebo increased slightly, so both ICERs decreased
(£9599 for placebo vs. immediate referral, and £20,592 for
lubiprostone vs. placebo). Prucalopride continued to be
dominated by lubiprostone.
We considered an extreme scenario where the effect of
placebo treatment was limited to 2 weeks. In this case, the
ICER for placebo versus immediate referral increased to
£77,959/QALY and the ICER for lubiprostone versus
placebo decreased to £17,926/QALY because the benefit of
placebo was much reduced. However, the long-term effi-
cacy of placebo is currently unknown.
4 Discussion
This analysis showed that, at a willingness to pay of
£20,000–30,000/QALY, placebo was the most cost-effec-
tive treatment. Lubiprostone was cost effective compared
with immediate referral and dominated prucalopride but
Fig. 3 Cost-effectiveness
acceptability curve
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was not cost effective compared with placebo in the base
case. NICE recommended lubiprostone on the grounds that
it was at least as effective as prucalopride and has a slightly
lower acquisition cost but noted that evidence is insuffi-
cient to demonstrate it is cost effective compared with
placebo.
The major source of uncertainty in determining whether
lubiprostone represents value for money therefore is in
understanding the treatment pathway without lubiprostone.
This appears to be driven by the lack of clear guidelines for
the treatment of patients despite the condition being rela-
tively common. If lubiprostone is positioned as a treatment
for people for whom at least two previous laxatives have
failed and in whom invasive procedures are being consid-
ered, assuming patients would receive standard laxatives
(represented by placebo) may not be appropriate. This
would indicate the most appropriate comparison is versus
immediate referral. For these patients, lubiprostone avoids
or delays referrals to investigations and invasive proce-
dures, partially offsetting the costs of the drug, with patient
quality of life improved (as shown by the QALY gain).
The comparison against prucalopride demonstrated that
lubiprostone was cost effective in all scenarios. Although it
was not possible to conduct analyses using the same end-
point that was used to model response to lubiprostone and
placebo, it was possible to conduct indirect comparisons on
seven different endpoints across a range of efficacy out-
comes. Whilst lubiprostone appeared more effective in
most, this rarely reached statistical significance, leading to
uncertainty as to whether prucalopride or lubiprostone is
the more effective treatment. In scenario analysis where
prucalopride was assumed to be more effective than
lubiprostone, whilst prucalopride generated more QALYs,
lubiprostone remained cost effective because of lower
costs. A recent network meta-analysis in CIC included
lubiprostone and prucalopride, with change in SBM as the
Fig. 4 Tornado diagram using
95% confidence interval of
parameters: a lubiprostone vs.
placebo and b lubiprostone vs.
prucalopride. GP general
practitioner, ITT intention to
treat, QALYs quality-adjusted
life-years, SBM spontaneous
bowel movement
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outcome. Although the numerical results of this network
meta-analysis were not identical to our analysis (due to
differences in methods and included studies), the study
found the two drugs to be equally effective, similar to the
conclusions of our analyses [38]. When both are equally
effective, lubiprostone is cost saving because of lower drug
costs. However, it should be noted that these results may
not apply in a subgroup of elderly patients, where the dose
and hence cost of prucalopride is lower. We were unable to
estimate the relative cost effectiveness of lubiprostone and
prucalopride in this specific population as we did not have
data for the effectiveness of both treatments in this sub-
group alone. It would not be appropriate to assume the
same effectiveness as the base case because effectiveness
may differ in the elderly population, particularly when
considering a reduced dose of prucalopride.
This is the first study to consider the cost effectiveness
of lubiprostone in the treatment of CIC in the UK, though
an economic evaluation was performed for prucalopride in
this indication as part of a previous NICE appraisal [18].
The results of the previous economic model showed
prucalopride to have an ICER of £16,000 compared with
placebo, which is lower than the ICER for this comparison
from our model (£79,670). This difference appears to be
mainly due to different model structures and time horizons.
We consider our model to be more accurate, as it reflects
the treatment pathway after failure of the initial treatment
and over a much longer time horizon, after which patients
will be in the same health states, and thus consequences
from treatment were appropriately costed. A targeted lit-
erature search identified four other economic evaluations in
chronic constipation. One study looked at the cost effec-
tiveness of prucalopride in the Netherlands; this economic
evaluation used the same model structure, comparators and
assumptions as the aforementioned previous NICE
appraisal but used costs relevant to Dutch payers and
considered a longer time horizon [39]. Huang et al. [40]
developed a decision tree model comparing linaclotide
with lubiprostone in the USA. Response to therapy was
defined as (1) having one of the best two satisfaction
answers of a 5-point global treatment satisfaction scale at
week 4 or (2) having a weekly SBM frequencyC 4 at week
4. The time horizon used was 4 weeks, and results showed
both treatments resulted in equal QALYs, so only a cost
comparison was made. Linaclotide is not licensed in the
UK so was not included in our model. Taylor et al. [41] and
Guest et al. [34] compared Macrogol 3350 and Macrogol
4000 to lactulose, respectively. Both studies used a deci-
sion tree model with timelines of 3 and 6 months.
In the appraisal of lubiprostone, the NICE appraisal
committee concluded the model structure was valid for the
decision problem, on account of it considering treatment
stopping rules, discontinuation and referral to secondary
care. The committee reviewed the data sources and
assumptions and found them to be appropriate [32]. This
process, together with the critique of the model by an
independent economist, and verification of the model cal-
culations by an independent review group, addresses some
of the best practices recommended for model validation
[42]. An important part of validation that we were unable
to address involves comparing predicted results with those
observed in longitudinal studies. We used the long-term
published lubiprostone studies as data sources in the model,
so could not then validate against them. We could not
identify any additional long-term follow-up studies con-
ducted since we developed the model. This is not surpris-
ing, given there was no requirement from reimbursement or
licensing agencies to collect additional data. Routine col-
lection of long-term data would facilitate validation of
future modelling studies in functional bowel disorders.
Some limitations to the model are linked to the data
available. Most notable here are the assumptions around
the extrapolation of efficacy and discontinuation data
beyond the relatively short clinical trials (48 weeks for the
open-label studies [12]), despite the chronic nature of the
condition. Despite the limitations of the data, sensitivity
analyses demonstrated that the results of the model were
robust to different data sources and assumptions, with
lubiprostone being cost effective compared with prucalo-
pride in all scenarios, and not cost effective compared with
placebo except in extreme scenarios.
In conclusion, lubiprostone has been shown to be a cost-
effective treatment compared with prucalopride or imme-
diate referral in CIC but not compared with placebo. The
implementation of the guidance issued by NICE [32]
should increase the quality of life for patients with CIC for
whom previous treatments have failed, should provide a
further treatment option, and may save NHS resources
depending on the comparator displaced in practice—either
in avoiding unnecessary tests or, more likely, in displacing
prucalopride, which has a higher acquisition cost. As the
number of health technology appraisals in this area
increases, we hope this leads to the provision of further
evidence-based guidelines in the area and clarification on
the most appropriate treatment pathway.
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